ATE525349T1 - Pharmazeutische prostaglandinzusammensetzungen - Google Patents

Pharmazeutische prostaglandinzusammensetzungen

Info

Publication number
ATE525349T1
ATE525349T1 AT08719314T AT08719314T ATE525349T1 AT E525349 T1 ATE525349 T1 AT E525349T1 AT 08719314 T AT08719314 T AT 08719314T AT 08719314 T AT08719314 T AT 08719314T AT E525349 T1 ATE525349 T1 AT E525349T1
Authority
AT
Austria
Prior art keywords
prostagland
pharmaceutical
compositions
glaucoma
employed
Prior art date
Application number
AT08719314T
Other languages
English (en)
Inventor
Soldato Piero Del
Giancarlo Santus
Anna Sparatore
Original Assignee
Ctg Pharma S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ctg Pharma S R L filed Critical Ctg Pharma S R L
Application granted granted Critical
Publication of ATE525349T1 publication Critical patent/ATE525349T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08719314T 2007-05-25 2008-03-06 Pharmazeutische prostaglandinzusammensetzungen ATE525349T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001073A ITMI20071073A1 (it) 2007-05-25 2007-05-25 Composizioni farmaceutiche di prostaglandine
PCT/IB2008/000620 WO2008146105A1 (en) 2007-05-25 2008-03-06 Prostaglandin pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE525349T1 true ATE525349T1 (de) 2011-10-15

Family

ID=39523705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08719314T ATE525349T1 (de) 2007-05-25 2008-03-06 Pharmazeutische prostaglandinzusammensetzungen

Country Status (5)

Country Link
US (1) US20100168216A1 (de)
EP (1) EP2170819B1 (de)
AT (1) ATE525349T1 (de)
IT (1) ITMI20071073A1 (de)
WO (1) WO2008146105A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201117095D0 (en) * 2011-09-30 2011-11-16 Univ Exeter The Novel hydrogen sulfide releasing compounds
EP3148528A1 (de) 2014-06-02 2017-04-05 University of Exeter Kombinationen eines fotosensibilisators mit einem schwefelwasserstoffdonor, thioredoxininhibitor oder nitroxid zur verwendung in der fotodynamischen therapie
FR3063642A1 (fr) * 2017-03-07 2018-09-14 Elodie Petitjean Traitement du glaucome a l'aide d'un inhibiteur specifique de la production de ros d'origine mitochondriale
US12516028B2 (en) * 2020-04-21 2026-01-06 Flexsys Ip Holdings, Llc Triazinanes possessing thiosulfonate end-groups and methods of making them

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
US20100168216A1 (en) 2010-07-01
EP2170819B1 (de) 2011-09-21
EP2170819A1 (de) 2010-04-07
ITMI20071073A1 (it) 2008-11-26
WO2008146105A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
CR20110131A (es) Derivados de prostaglandinas
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
ATE517882T1 (de) Chinolinderivate
BR112012018345A2 (pt) "compostos de heteroarila, bem como composições e usos dos mesmos"
EA200901319A1 (ru) Композиции для назального введения
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
UY30500A1 (es) Compuestos de azabencimidazolilo
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
UY32069A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-triifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
EA201070483A1 (ru) Новые офтальмологические композиции
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
EA201290229A1 (ru) Производные спиролактама и их применение
ITMI20070890A1 (it) Composizioni oftalmiche per il trattamento della ipertensione oculare e del glaucoma
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties